Ergomed (AIM:ERGO) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ERGO 주식 개요

Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally.

회사 소개

ERGO 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	3/6
과거 실적	3/6
재무 상태	6/6
배당금	0/6

보상

수익은 매년 14.17% 증가할 것으로 예상됩니다.

지난 1년간 수익이 12.3% 증가했습니다.

위험 분석

최근 3개월간 주가 변동성

지난 1년 동안 주주가 희석되었습니다.

Ergomed plc 경쟁사

hVIVO

AIM:HVO

UK£185.1m

C4X Discovery Holdings

AIM:C4XD

UK£30.3m

Genus

LSE:GNS

UK£1.1b

Bioventix

AIM:BVXP

UK£225.8m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Ergomed
과거 주가
현재 주가	UK£13.46
52주 최고치	UK£13.80
52주 최저치	UK£8.95
베타	0.79
11개월 변경	0.90%
3개월 변경 사항	21.26%
1년 변경 사항	3.54%
33년 변화	67.41%
5년 변화	812.54%
IPO 이후 변화	728.31%

최근 뉴스 및 업데이트

Recent updates

If You Had Bought Ergomed (LON:ERGO) Stock Five Years Ago, You Could Pocket A 643% Gain Today

Feb 22

Has Ergomed plc's (LON:ERGO) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Jan 18

Ergomed plc's (LON:ERGO) Intrinsic Value Is Potentially 20% Below Its Share Price

Dec 13

We Think Ergomed's (LON:ERGO) Statutory Profit Might Understate Its Earnings Potential

Nov 23

주주 수익률

	ERGO	GB Life Sciences	GB 마켓
7D	0.1%	-5.3%	-0.4%
1Y	3.5%	-40.9%	6.1%

수익률 대 산업: ERGO 지난 1년 동안 -40.9 %를 반환한 UK Life Sciences 산업을 초과했습니다.

수익률 대 시장: ERGO 지난 1년 동안 6.1 %를 반환한 UK 시장을 초과했습니다.

가격 변동성

Is ERGO's price volatile compared to industry and market?
ERGO volatility
ERGO Average Weekly Movement	8.1%
Life Sciences Industry Average Movement	7.1%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.1%
10% least volatile stocks in GB Market	2.8%

안정적인 주가: ERGO 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: ERGO 의 주간 변동성( 8% )은 지난 1년 동안 안정적이었지만 여전히 UK 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
1997	1,400	n/a	www.ergomedplc.com

Ergomed plc 기본 사항 요약

Ergomed 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ERGO 기본 통계
시가총액	UK£701.05m
수익(TTM)	UK£15.00m
수익(TTM)	UK£152.09m

46.7x

P/E 비율

4.6x

P/S 비율

ERGO 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ERGO 손익 계산서(TTM)
수익	UK£152.09m
수익 비용	UK£68.82m
총 이익	UK£83.27m
기타 비용	UK£68.27m
수익	UK£15.00m

최근 보고된 수익

Jun 30, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	0.29
총 마진	54.75%
순이익 마진	9.86%
부채/자본 비율	0%

ERGO 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ERGO 주식 개요

보상

위험 분석

Ergomed plc 경쟁사

AIM:HVO

UK£185.1m

AIM:C4XD

UK£30.3m

LSE:GNS

UK£1.1b

AIM:BVXP

UK£225.8m

가격 내역 및 성능

최근 뉴스 및 업데이트

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Recent updates

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Now 20% undervalued after recent price drop

Is It Time To Consider Buying Ergomed plc (LON:ERGO)?

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ergomed plc, Annual General Meeting, Jun 22, 2023

At UK£9.74, Is Ergomed plc (LON:ERGO) Worth Looking At Closely?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Ergomed plc to Report Fiscal Year 2022 Results on Mar 21, 2023

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Ergomed Announces Two Senior Appointments to its Executive Team

Ergomed Strengthens Executive Management Team

Ergomed Strengthens Executive Management Team

Ergomed plc (LON:ERGO) Shares Could Be 21% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: UK£0.15 (vs UK£0.14 in 1H 2021)

Ergomed plc to Report First Half, 2022 Results on Sep 27, 2022

Investor sentiment improved over the past week

Should You Be Adding Ergomed (LON:ERGO) To Your Watchlist Today?

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc Appoints Anne Whitaker as Independent Non-Executive Director

Full year 2021 earnings: EPS misses analyst expectations

Ergomed plc, Annual General Meeting, Jun 10, 2022

Consensus EPS estimates increase by 11%

Consensus forecasts updated

Less than half of directors are independent

Now 21% undervalued

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Full year 2021 earnings: EPS misses analyst expectations

Does Ergomed (LON:ERGO) Deserve A Spot On Your Watchlist?

John Dawson, Cbe Joins the Board of Ergomed plc as Independent Non-Executive Director and Chair of the Audit Committee

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc to Report Fiscal Year 2021 Results on Mar 29, 2022

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

Ergomed plc (AIM:ERGO) acquired Adamas Consulting Ltd. at an enterprise value of £24.2 million.

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

Investor sentiment deteriorated over the past week

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Ergomed (LON:ERGO) Passed With Ease

First half 2021 earnings released: EPS UK£0.14 (vs UK£0.089 in 1H 2020)

Calculating The Intrinsic Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out Ergomed (LON:ERGO) Before It's Too Late

Getting In Cheap On Ergomed plc (LON:ERGO) Might Be Difficult

Ergomed plc (LON:ERGO) Shares Could Be 31% Above Their Intrinsic Value Estimate

Price target increased to UK£13.65

Non-Executive Director has left the company

Investor sentiment improved over the past week

Do Ergomed's (LON:ERGO) Earnings Warrant Your Attention?

Full year 2020 earnings released